Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus A Neubauer

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Ethics|June 10, 2003
Quality improvement and ethics: performance improvement in an oncology practiceJohn E Hennessy, Marcus A Neubauer
Journal of Oncology Practice|March 19, 2015
Improving incidence of code status documentation through process and disciplineMarcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman
Clinical Lung Cancer|December 16, 2005
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II studyDonald A Richards, Paul Richards, David Bodkin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancerCharles H Weissman, Craig H Reynolds, Marcus A Neubauer, et al.
Clinical Lung Cancer|February 8, 2005
Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2Marcus A Neubauer, Craig H Reynolds, Marcos G Joppert, et al.
Palliative Medicine Reports|July 5, 2021
Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care ModelJ Russell Hoverman, B Brooke Mann, Sara Phu, et al.
Clinical Genitourinary Cancer|October 10, 2006
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancerMichael Kolodziej, Marcus A Neubauer, Steven R Rousey, et al.
Lung Cancer (Amsterdam, Netherlands)|March 28, 2003
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancerMark A Socinski, Marcus A Neubauer, Jairo Olivares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancerMarcus A Neubauer, David H Garfield, Paul R Kuerfler, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Ethics|June 10, 2003
Quality improvement and ethics: performance improvement in an oncology practiceJohn E Hennessy, Marcus A Neubauer
Journal of Oncology Practice|March 19, 2015
Improving incidence of code status documentation through process and disciplineMarcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman
Clinical Lung Cancer|December 16, 2005
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II studyDonald A Richards, Paul Richards, David Bodkin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancerCharles H Weissman, Craig H Reynolds, Marcus A Neubauer, et al.
Clinical Lung Cancer|February 8, 2005
Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2Marcus A Neubauer, Craig H Reynolds, Marcos G Joppert, et al.
Palliative Medicine Reports|July 5, 2021
Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care ModelJ Russell Hoverman, B Brooke Mann, Sara Phu, et al.
Clinical Genitourinary Cancer|October 10, 2006
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancerMichael Kolodziej, Marcus A Neubauer, Steven R Rousey, et al.
Lung Cancer (Amsterdam, Netherlands)|March 28, 2003
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancerMark A Socinski, Marcus A Neubauer, Jairo Olivares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancerMarcus A Neubauer, David H Garfield, Paul R Kuerfler, et al.
Pageof 3